Here, we present the first case showing the anti‐tumor efficacy of afatinib and the second case showing the anti‐tumor efficacy of osimertinib, respectively, in patients with EGFR L861R‐positive lung adenocarcinoma. This evidence concerns the gene EGFR and lung adenocarcinoma.